Diabetes is a scary diagnosis for anyone. When people with the disease struggle to manage their blood sugar levels, they can experience significant, life-threatening and costly complications such as heart attack, stroke, kidney failure, amputation and blindness. Fortunately, diabetes can be well-managed with comprehensive access to health care services, including medicines.
To that end, PhRMA recently partnered with GlobalData to demonstrate how, when people with diabetes enrolled in Medicaid are not able to adhere to their treatment regimen, it affects their health outcomes. The tool GlobalData created — known as the Medicaid Diabetes Adherence Online Tool — demonstrates how states can avoid costly medical complications if adherence to anti-diabetic medicines is improved over six years. Specifically, the tool provides analyses that show differences in the impacts diabetes has on various communities, as well as opportunities to improve health equity and reduce health costs, by race, ethnicity and age.
The new tool is being shared with the goal of helping policymakers and health care professionals to find ways to improve adherence to anti-diabetic medication among Medicaid beneficiaries. The following statistics highlight areas to be addressed:
While diabetes is a chronic condition that can be managed, the burden of the disease falls disproportionately on communities of color.
- Diabetes disproportionately affects American Indians/Alaska Natives (14.7%), Hispanics (12.5%) and non-Hispanic Blacks (11.7%) compared to White populations. Communities of color are also more likely to experience complications from diabetes. The rate of diabetes-related deaths among Native Americans/Alaska Native populations is 2.3 times higher than non-Hispanic Whites, and Hispanics are 1.3 times more likely to die from diabetes than non-Hispanic Whites.
- Communities of color are also less likely to receive recommended diabetes preventive care, such as hemoglobin A1c (HbA1c) testing, annual cholesterol screening and retinal examination.
Because so many people with diabetes are covered by Medicaid, access to care through Medicaid plays an important role in helping individuals manage their disease.
- An estimated 12% of Medicaid enrollees have diabetes, and Medicaid is estimated to cover 15% of all individuals with the disease.
Despite the low cost of medicines in Medicaid, enrollees take their medication as prescribed only about 75% of the time.
- Medicines in Medicaid have limited cost sharing from $1-$4, and rebates from manufacturers help to offset costs for states and the federal government. Despite these limited costs, some enrollees continue to face access barriers.
+++
The new Medicaid Diabetes Adherence Calculator provides a visual comparison across 50 states and Washington, D.C. To use the tool, click here. For more information about Medicaid, please visit www.PhRMA.org/Medicaid. See more resources geared toward policy solutions in all 50 states at www.PhRMA.org/States.
Reid Porter
Reid Porter is senior director of public affairs at PhRMA, where he focuses on key policy priorities, member engagement and state media relations. He brings over two decades of experience leading communications and managing complex issues across the biopharmaceutical, technology and energy sectors. Porter holds a B.A. from Middlebury College, where he double‑majored in English and Spanish, and a graduate certificate in Publishing from Columbia University. Outside of work, he enjoys writing, traveling, cheering for the Green Bay Packers, playing and watching soccer, playing the violin, rereading Hemingway novels and spending time with family.
Delivering breakthroughs and lower costs for patients
The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid
Ensuring access to affordable medicines for patients through Medicaid
CMS, don’t fall behind the rest of the medical community on obesity
The real cost of denying access to medicines in Medicaid
Celebrating advances in diabetes research
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
Did the administration consider the value of innovative diabetes medicines in price setting process?
Medicaid by the numbers
Providing affordable access to medicines in Medicaid
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
Increased use of prior authorization in Medicaid is blocking access for patients
Manufacturers provided $42 billion in Medicaid discounts in 2021 alone
CMS should rethink proposed changes to the Medicaid Drug Rebate Program | PhRMA
4 key facts on medicine prices and spending
States can support access to medicine as COVID-19 Public Health Emergency ends
Study finds hepatitis C cure saved Medicaid $15 billion
New data show how insurers and middlemen shift Rx costs onto patients
Busting 3 Myths About Copay Coupons
Insulin and reconciliation
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
Medicaid 101: Three charts on access and spending
3 factors impacting medication adherence for patients with diabetes
Insurers shift medicine costs to patients with severe chronic illnesses
Tennessee’s Medicaid demonstration fails patients
New insulin report highlights how incentives benefit middlemen, harm patients
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Sharing rebates can improve access to medicines and increase health equity
Recent administration actions undermine patient assistance programs
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
PhRMA submits comments to CMS on Medicaid proposed rule
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Addressing barriers that inhibit value-based contracts
PhRMA comments to Congress on Cures 2.0 call to action
Guest post: H.R.3 is the wrong approach to help patients like me
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
Guest post: Sharing discounts and rebates is the right thing to do
Ask About Adherence: Hepatitis C cures will save Medicaid $12 billion by 2022
New report shows more than 160 medicines in development for diabetes and related conditions
Five key facts about the market for insulins
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
OptumRX: Sharing rebates with patients is “worth it”
Six key facts about the market for insulins
Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment
Reality check: Value-based contracts are good for patients
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Ask About Adherence: Private-sector collaboration can lead to savings and care improvement
New report shows better diabetes management saves money and improves patient outcomes
Protect your health: Important disaster preparedness tips for Harvey and Irma
Ask About Adherence: Discussion on medication adherence as national priority
Medicare Monday: Positive impact of Part D on America’s seniors
A critical opportunity to prevent prescription drug abuse
Medicare Monday: A discussion on affordability and access to medicines
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
Diabetes
Adherence
Medicaid
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid